When used in combination with PD-1, tumor infiltration of Tregs is significantly reduced, and the CD8 T/Treg ratio increases (Hao et al., 2023), thereby avoiding the immune desert phenotype, which explains the effective synergy of immunogenic chemotherapeutic drugs and ICB. This evidence concerns the gene CD8A and neoplasm.